Abstract:
Introduction: Multidrug-resistant tuberculosis (MDR-TB) is a common public health problem affecting pregnant women. However, the impact of MDR-TB and its medication on pregnancy and perinatal outcomes has been poorly understood and inconsistently reported. Therefore, using the available literature, we aim to determine whether MDR-TB and its medications during pregnancy impact maternal and perinatal outcomes. Methods and analysis: This systematic review and meta-Analysis will adhere to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Systematic searches will be conducted in PubMed, Scopus and Web of Science on 10 February 2020 for studies that reported adverse maternal and perinatal outcomes due to MDR-TB and/or its medication. The search will be performed without language and time restrictions. Adverse birth outcomes include miscarriage or abortion, stillbirth, preterm birth, low birth weight, small and large for gestational age, and neonatal death. Two independent reviewers will screen search records, extract data and assess the quality of the studies. The Newcastle-Ottawa Quality Assessment Scale will be used to assess the methodological quality of the included studies. In addition to a narrative synthesis, a random-effects meta-Analysis will be conducted when sufficient data are available. I 2 statistics will be used to assess the heterogeneity between studies. Ethics and dissemination: As it will be a systematic review and meta-Analysis based on previously published evidence, there will be no requirement for ethical approval. Findings will be published in a peer-reviewed journal and will be presented at various conferences.
Impact of multidrug-resistant tuberculosis and its medications on adverse maternal and perinatal outcomes: Protocol for a systematic review and meta-Analysis
We aim to determine whether multidrug-resistant tuberculosis and its medications during pregnancy impact maternal and perinatal outcomes